News & Events about Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE Get Rating) had its price objective lifted by Royal Bank of Canada from $49.00 to $51.00 in a research report report published on Tuesday , Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical companys ...
XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101 Phase 3 program development and cash runway into 2026 BURNABY, British Columbia, Jan. 09, 2023 (GLOBE ...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE Get Rating) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical volume of 165 put options. Analyst Upgrades and ...
Globe Newswire
2 months ago
Company Presents Additional Positive Data from Open Label Extension of Phase 2b X-TOLE Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022 BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon ...
Globe Newswire
3 months ago
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFabio will provide ...